SAN DIEGO, CA & Taikang, China, May 17, 2022 (Globe Newswire) — Connect Biopharma Holdings Ltd. (Nasdaq: CNTB) (“Connect Biopharma” or “The Company”), a global clinical-stage biopharmaceutical company dedicated to improving Is. Data describing the immunological profile of CBP-201 will be presented, based on preclinical experiments in the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, as a clinical measure of Th2-driven inflammation. Will demonstrate a deficiency in a recognized biomarker. Additionally, the company will report different binding epitopes, higher binding affinity, and increased potency with CBP-201 demonstrating better target binding properties compared to dupilumab. The data will be presented in a poster at the Society for Investigative Dermatology Annual Conference, May 18-21 at the Oregon Convention Center, Portland, Oregon.
poster presentation details
Title: CBP-201, a new and differentiated IL-4Ra target antibody being evaluated in Th2 inflammatory diseases
Submitted by: Paul A. Smith, VP, Discovery Biology, Connect Biopharma
The poster is available on the Presentations and Publications section of the company’s website: https://www.connectbiopharm.com/our-science/presentations-and-publications/.
About atopic dermatitis
Atopic dermatitis (AD), which has an estimated lifespan of up to 20% and is increasing globally, is the most commonly diagnosed chronic inflammatory skin disorder. It is characterized by skin barrier disruption and immune dysregulation. In the United States, it is estimated that 26.1 million people have AD, of whom 6.6 million have moderate to severe disease. Estimates of the prevalence of AD in China show an increase over time and recent longitudinal studies have reported a dermatologist-diagnosed prevalence of 7.8% in Chinese outpatients attending tertiary hospitals. In addition, more than 58% of adults with moderate to severe AD have disease that physicians consider to be inadequately controlled by approved therapeutic modalities, including topical anti-inflammatory agents and systemic agents.
CBP-201. About this
CBP-201, internally discovered using Connect Biopharma’s proprietary Immune Modulation Technology platform, is an antibody designed to target the interleukin-4 receptor alpha (IL-4Rα), which is involved in atopic dermatitis (AD). ) is a validated target for the treatment of many inflammatory diseases. ) CBP-201 was well tolerated and showed evidence of clinical activity in a phase 2B clinical trial (NCT044444752) in adult patients with moderate-to-severe atopic dermatitis, the current clinical The comparison of data from trials suggests the potential for a differentiated efficacy profile. Biological standard of care medicine. CBP-201 is also being evaluated in a China-specific pivotal trial in adults with moderate to severe atopic dermatitis (NCT05017480); and in a phase 2b trial in adult patients with moderate to severe persistent asthma (NCT04773678).
About Connect Biopharma Holdings Limited
Connect Biopharma is a global, clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell-driven research. It is building a rich pipeline of internally designed, wholly-owned, small molecules and antibodies, using functional cellular assays with T cells and the discovery of potent product candidates against validated immune targets. does. Its lead product candidate, CBP-201, is an antibody designed to target the interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. The company’s second most advanced product candidate, CBP-307, is a modulator of the T-cell receptor known as S1P1 in development for the treatment of UC. Clinical development has begun for its third product candidate, CBP-174, a peripherally acting antagonist of the histamine receptor 3, for the treatment of AD-associated pruritus.
With operations in the United States and China, Connect Biopharma is building a rich global pipeline of molecules and antibodies targeting multiple aspects of T cell biology. For additional information, please visit www.connectbiopharm.com,
Connect Biopharma warns that the statements contained in this press release are not statements of historical facts and are forward-looking statements. “might,” “might,” “will,” “will,” “should,” “expect,” “plan,” “estimate,” “believe,” “estimate,” “intend,” “predict” Words like “. The negative or other comparable terminology of “”search,” “contemplation,” “look forward,” “prospective,” “continue” or “project” or the negative or other comparable terminology of these terms is intended to identify forward-looking statements. These statements include the Company’s own Contains statements regarding plans to pursue development of product candidates, the potential of such product candidates, the potential to achieve any given benefit or profile, trends within the ulcerative colitis population, and partnerships for the future development of CBP-307 The inclusion of forward-looking statements shall not be construed as a representation by Connect Biopharma that any of its plans will be achieved. The risks and uncertainties inherent in the Connect Biopharma business and of the Company with the Securities and Exchange Commission (“SEC”) Other risks described in the filing could cause actual results to differ materially from those set out in this release, including the company’s annual report on Form 20-F filed with the SEC on March 31, 2022, and its other reports. Undue reliance on these forward-looking statements to investors Be warned not to keep, speak only as of the date herein, and Connect Biopharma undertakes no obligation to modify or update this news release to reflect events or circumstances. Further information about these and other risks is included in Connect Biopharma’s filings with the SEC which are available on the SEC’s website (www.sec.gov) and Connect Biopharma’s website (www.connectbiopharm.com) under the heading “Investors”. Huh. All forward-looking statements are fully qualified by this warning statement. This precaution has been taken under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act 1995.
Lazar Fin Partners
David Carey (IR)
T: +1-(212) 867-1768
Glenn Silver (media)